Foundation review: Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies

Drug Discovery Today

Volumn 17, Issue 13-14, 2012, Pages 671-684

  Broussalis, Erasmia ^a   Trinka, Eugen ^a   Killer, Monika ^a   Harrer, Andrea ^a   McCoy, Mark ^a   Kraus, Jörg ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDROXYFLAVONE; ABCIXIMAB; ANCROD; ANTITHROMBOCYTIC AGENT; APTIGANEL; BATROXOBIN; CHOLINESTERASE INHIBITOR; CITICOLINE; DEFERASIROX; DEFEROXAMINE; DESMOTEPLASE; DEXTRORPHAN; DISUFENTON SODIUM; EBSELEN; ELIPRODIL; EPTIFIBATIDE; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FIBRINOGEN RECEPTOR ANTAGONIST; GAVESTINEL; GRANULOCYTE COLONY STIMULATING FACTOR; HERICENONE B; IFENPRODIL; MLC 601; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU 2000; NORPHENAZONE; OZAGREL; PLACEBO; TENECTEPLASE; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; NEUROPROTECTIVE AGENT; NEW DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE ISCHEMIC HEMISPHERIC STROKE; ACUTE STROKE THROMBOLYSIS; ASTROCYTE; BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL DEATH; CHINESE MEDICINE; COST; DISABILITY; DRUG MEGADOSE; EXPERIMENTAL MODEL; EXPERIMENTAL STUDY; GLASGOW OUTCOME SCALE; HUMAN; MICROGLIA; MONOCYTE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; RANKIN SCALE; RATING SCALE; REVIEW; SCORING SYSTEM; STROKE; TREATMENT OUTCOME; ANIMAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG SCREENING; OCCLUSIVE CEREBROVASCULAR DISEASE;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; INTRACRANIAL THROMBOSIS; NEUROPROTECTIVE AGENTS; STROKE; TREATMENT OUTCOME;

EID: 84863510643     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.011     Document Type: Review

References (103)

1. V.L. Roger American heart association statistics committee and stroke statistics subcommittee Circulation 123 2006 18 209
2. T. Truelsen Stroke incidence and prevalence in Europe: a review of available data Eur. J. Neurol. 13 2006 581 598 (Pubitemid 43873630)
3. H. Quintard MLC901, a Traditional Chinese Medicine protects the brain against global ischemia Neuropharmacology 61 2011 622 631
4. R. Sacco Experimental treatments for acute ischemic stroke Lancet 639 2007 331 341 (Pubitemid 46136492)
5. W. Hacke for The DIAS Study Group The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase Stroke 36 2005 66 73 (Pubitemid 40054177)
6. U.S. National Institutes of Health. A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke
7. E.C. Haley Tenecteplase in Stroke Investigators Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial Stroke 41 2010 707 711
8. D.E. Levy Ancrod Stroke Program (ASP) Study Team Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies J. Stroke Cerebrovasc. Dis. 18 2009 23 27
9. D.E. Levy Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program Stroke 40 2009 3796 3803
10. W.K. You Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris FEBS Lett. 30 2004 67 73
11. E.I. Gusev Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study) Zh Nevrol Psikhiatr Im S S Korsakova 106 2006 31 34
12. G. Xu Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention Blood Coagul. Fibrinolysis 18 2007 193 197 (Pubitemid 46232842)
13. B. Cortese Combined, superselective pharmacological management of large coronary thrombus burden J. Invasive Cardiol. 21 2009 168 171
14. A.M. Pancioli CLEAR Trial Investigators The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial Stroke 39 2008 3268 3276
15. K. Mori Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced platelet aggregation Phytomedicine 17 2010 1082 1085
16. A.R. Green, and A. Shuaib Therapeutic strategies for the treatment of stroke Drug Discov. Today 11 2006 681 693 (Pubitemid 44056287)
17. O. Weinreb Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities Antioxid. Redox Signal. 15 2010 919 949
18. Y. Zhao, and D.A. Rempe Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function J. Cereb. Blood Flow Metab. 31 2011 1412 1423
19. G. Rosenberg for the MACSI investigators The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study Int. J. Stroke 6 2011 362 367
20. D. Méthy Beneficial effect of dipyridyl, a liposoluble iron chelator against focal cerebral ischemia: in vivo and in vitro evidence of protection of cerebral endothelial cells Brain Res. 1193 2008 136 142
21. J.K. Strecker Effects of G-CSF treatment on neutrophil mobilization and neurological outcome after transient focal ischemia Exp. Neurol. 222 2009 108 113
22. M. Hasselblatt Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke Acta Neuropathol. 113 2006 45 511
23. W.R. Schäbitz AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke Stroke 41 2010 2545 2551
24. J.Y. Seo Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes J. Neurol. Sci. 285 2009 88 94
25. K. Yamagata Protective effects of ebselen, a seleno-organic antioxidant on neurodegeneration induced by hypoxia and reperfusion in stroke-prone spontaneously hypertensive rat Neuroscience 153 2008 428 435
26. E.D. Hall Antioxidant therapies for traumatic brain injury Neurotherapeutics 7 2010 51 61
27. E. Sena Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke Stroke 38 2007 388 394 (Pubitemid 46184311)
28. M.R. Macleod Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality Stroke 39 2008 2824 2829
29. M. Culot Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study Brain Res. 1294 2009 144 152
30. P.T. Akins, and R.P. Atkinson Glutamate AMPA receptor antagonist treatment for ischaemic stroke Curr. Med. Res. Opin. 18 2002 9 13
31. Y. Yang Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats Neurosurgery 98 2003 397 403 (Pubitemid 36151038)
32. Y. Zhao Neuroprotection against excitotoxic and ischemic insults by bis(12)-hupyridone, a novel anti-acetylcholinesterase dimer, possibly via acting on multiple targets Brain Res. 3 2011 100 109
33. J. Chen Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity Neurosci. Lett. 25 2011 181 185
34. M. Kuszczyk 1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity Pharmacol. Rep. 62 2010 1041 1050
35. S.I. Cho Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke Drug News Perspect. 23 2010 549 556
36. V. Mishra The neuroprotective effects of NMDAR antagonist, ifenprodil and ASIC1a inhibitor, flurbiprofen on post-ischemic cerebral injury Brain Res. 10 2011 152 160
37. H.J. Cho, and Y.J. Kim Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4191 cases Methods Find. Exp. Clin. Pharmacol. 31 2009 171 176
38. A. Dávalos, and J. Secades Citicoline preclinical and clinical update 2009-2010 Stroke 42 2011 36 39
39. M. Rodríguez-Yáñez, and J. Castillo Role of inflammatory markers in brain ischemia Curr. Opin. Neurol. 21 2008 353 357 (Pubitemid 351653988)
40. A. Tuttolomondo Inflammatory cytokines in acute ischemic stroke Curr. Pharm. Des. 14 2008 3574 3589
41. C. Heurteaux Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo Neuropharmacology 58 2010 987 1001
42. C. Chen Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery Stroke 40 2009 859 863
43. F. Campos Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study J. Cereb. Blood Flow Metab. 31 2011 1378 1386
44. B. Gold Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke Curr. Drug Targets 12 2011 243 255
45. T. Kawamura Prostaglandin E1 transported into cells blocks the apoptotic signals induced by nerve growth factor deprivation J. Neurochem. 72 1999 1907 1914 (Pubitemid 29185993)
46. R. Sheng Combined prostaglandin E1 and lithium exert potent neuroprotection in a rat model of cerebral ischemia Acta Pharmacol. Sin. 32 2011 303 310
47. K. Ruscher The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke Brain 134 2011 732 746
48. K. Vagnerova Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase Anesth. Analg. 103 2006 430 434 (Pubitemid 44140646)
49. T.C. Burns, and G.K. Steinberg Stem cells and stroke: opportunities, challenges and strategies Expert Opin. Biol. Ther. 11 2011 447 461
50. G. Yilmaz Induction of neuro-protective/regenerative genes in stem cells infiltrating post-ischemic brain tissue Exp. Transl. Stroke 2 2010 11
51. P.A. Walker Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFkappaB-mediated increase in interleukin-6 production Stem Cells Dev. 19 2010 867 876
52. Y. Kaneko Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to neuroprotection J. Pineal Res. 50 2011 272 280
53. H.J. Marti Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia Am. J. Pathol. 156 2000 965 976 (Pubitemid 30626954)
54. I. Zachary Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential Neurosignals 14 2005 207 721
55. Y. Wei Fingolimod provides long-term protection in rodent models of cerebral ischemia Ann. Neurol. 69 2011 119 129
56. A. Liesz FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia PLoS ONE 6 2011 E21312
57. Z. Zhang Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats Anesth. Analg. 97 2003 1776 1783 (Pubitemid 37475138)
58. L. Yang Opioid receptor agonists reduce brain edema in stroke Brain Res. 1383 2011 307 316
59. S. Yu Cinnamophilin, a novel thromboxane A2 receptor antagonist, isolated from Cinnamomum philippinense M. Eur. J. Pharmacol. 11 1994 85 91 (Pubitemid 24117081)
60. T.Y. Chen Cinnamophilin offers prolonged neuroprotection against gray and white matter damage and improves functional and electrophysiological outcomes after transient focal cerebral ischemia Crit. Care Med. 39 2011 1130 1137
61. C. Elango Hawthorn extract reduces infarct volume and improves neurological score by reducing oxidative stress in rat brain following middle cerebral artery occlusion Int. J. Dev. Neurosci. 27 2009 799 803
62. C. Elango, and S.N. Devaraj Immunomodulatory effect of Hawthorn extract in an experimental stroke model J. Neuroinflammation 30 2010 97
63. H. Kaur Modulation of neuroprotective effect of ischemic post-conditioning by dichlorobenzamil a Na(+)/Ca(2+) exchanger inhibitor in mice Biol. Pharm. Bull. 33 2010 585 591
64. K.W. Muir Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial Lancet 363 2004 439 445 (Pubitemid 38210060)
65. J.L. Saver Target brain: neuroprotection and neurorestoration in ischemic stroke Rev. Neurol. Dis. 1 2010 14 21
66. J.L. Saver Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy - magnesium (FAST-MAG) pilot trial Stroke 35 2004 106 108
67. T. Watanabe Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion Stroke 37 2006 1539 1545 (Pubitemid 44305739)
68. Y. Nonaka Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage Neurosci. Lett. 13 2009 156 161
69. L.C. Pettigrew Arundic Acid (ONO-2506) Stroke Study Group Safety and tolerability of arundic acid in acute ischemic stroke J. Neurol. Sci. 251 2006 50 56 (Pubitemid 44792138)
70. H. Higashino Immunohistochemical analysis of brain lesions using S100B and glial fibrillary acidic protein antibodies in arundic acid-(ONO-2506) treated stroke-prone spontaneously hypertensive rats J. Neural Transm. 116 2009 1209 1219
71. P. Teal A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT) Stroke 40 2009 3518 3525
72. B. Medhi Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice Indian J. Exp. Biol. 48 2010 793 799
73. T. Kinouchi Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats Stroke 43 2012 478 483
74. C. Kleinschnitz Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration PLoS Biol. 8 2010 pii: E1000479
75. G. Pentón-Rol C-Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils Brain Res. Bull. 86 2011 42 52
76. R. Ye Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats Neurochem. Int. 58 2010 391 398
77. R. Ye Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice Neuropharmacology 61 2011 815 824
78. J.E. Jung Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxidative signaling in ischemic stroke Stroke 42 2011 3574 3579
79. J.E. Jung Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection Mol. Neurobiol. 41 2010 172 179
80. C. Cheyuo Recombinant human MFG-E8 attenuates cerebral ischemic injury: its role in anti-inflammation and anti-apoptosis Neuropharmacology 62 2011 890 900
81. J. Yan Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke PLoS ONE 6 2011 27798
82. H.T. Le The protective effects of plasma gelsolin on stroke outcome in rats Exp. Transl. Stroke Med. 2 2011 13
83. L. Zhang Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia Stroke 41 2010 1001 1007
84. K. Wiegler The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator Cerebrovasc. Dis. 26 2008 360 366
85. R.L. Zhang Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke Stroke 39 2008 2830 2836
86. M. Alonso de Leciñana Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke J. Neurol. Sci. 25 2006 121 129
87. S. Amaro, and Á. Chamorro Translational stroke research of the combination of thrombolysis and antioxidant therapy Stroke 42 2011 1495 1499
88. T. Sumii, and E.H. Lo Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats Stroke 33 2002 831 836 (Pubitemid 34204013)
89. J.C. Chavez Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch Stroke 40 2009 558 563
90. A. Shuaib, and M.S. Hussain The past and future of neuroprotection in cerebral ischaemic stroke Eur. Neurol. 59 2008 4 14 (Pubitemid 350277253)
91. V.E. O'Collins 1026 experimental treatments in acute stroke Ann. Neurol. 59 2006 467 477 (Pubitemid 43358067)
92. A.C. Foster Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation J. Neurosci. 8 1988 4745 4754 (Pubitemid 19015157)
93. D.J. Gladstone Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions Stroke 33 2002 2123 2136 (Pubitemid 34840080)
94. J.R. Marler Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study Neurology 55 2000 1649 1655
95. W. Hacke Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N. Engl. J. Med. 359 2008 1317 1329
96. E. Auriel, and N.M. Bornstein Neuroprotection in acute ischemic stroke - current status J. Cell. Mol. Med. 14 2010 2200 2202
97. K.W. Muir, and D.G. Grosset Neuroprotection for acute stroke: making clinical trials work Stroke 30 1999 180 182 (Pubitemid 29029460)
98. A.E. Baird, and S. Warach Using pathophysiology in acute stroke trial Stroke 30 1999 1293
99. K.W. Muir Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design Stroke 33 2002 1545 1550 (Pubitemid 34619955)
100. H.P. Adams Jr. Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the trial of org 10172 in acute stroke treatment (TOAST) Neurology 53 1999 126 131 (Pubitemid 29329660)
101. G. Sulter Use of the Barthel index and modified Rankin scale in acute stroke trials Stroke 30 1999 1538 1541 (Pubitemid 29379599)
102. T. Brott Measurements of acute cerebral infarction: a clinical examination scale Stroke 20 1989 864 870 (Pubitemid 19188240)
103. B. Farrell The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results J. Neurol. Neurosurg. Psychiatry 54 1991 1044 1054